Internal Medicine, Rheumatology · Orange, CA
NPI
1306891346
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1010 W la Veta Ave Ste 360
Orange, CA, 92868
Phone (714) 245-0492
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
173,395 services
Medicare patients, 2024
917
Average age 75
Drug cost, 2024
$5.6M
4,151 prescriptions
Company payments, 2025
$4,754
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joo-Hyung Lee was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 98,000 times for 31 patients. In total Joo-Hyung Lee billed 173,395 services in 96 codes, and Medicare paid $1.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-12-07.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 98,000 | 31 | $3.64 | $356K |
| J0897 Injection, denosumab, 1 mg | Office | 16,080 | 166 | $20.59 | $331K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 14,072 | 20 | $8.34 | $117K |
| 99214 Office E&M - Established | Office | 3,160 | 863 | $103.68 | $328K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 2,242 | 758 | $13.19 | $30K |
| J9312 Injection, rituximab, 10 mg | Office | 2,160 | 11 | $61.17 | $132K |
| 86235 Immunoassay | Office | 1,841 | 209 | $17.57 | $32K |
| 85651 Clinical Chemistry | Office | 1,749 | 698 | $4.17 | $7,296 |
| 36415 Venipuncture Blood Collection | Office | 1,742 | 698 | $7.98 | $14K |
| 85025 Blood Count | Office | 1,738 | 698 | $7.60 | $13K |
| 86141 Clinical Chemistry | Office | 1,707 | 686 | $12.66 | $22K |
| 84160 Clinical Chemistry | Office | 1,630 | 666 | $5.50 | $8,960 |
| 82565 Clinical Chemistry | Office | 1,629 | 666 | $5.02 | $8,178 |
| 84520 Clinical Chemistry | Office | 1,628 | 666 | $3.87 | $6,300 |
| 82150 Clinical Chemistry | Office | 1,626 | 666 | $6.35 | $10K |
By year: 2022 $1.6M for 184,072 services; 2023 $1.7M for 193,874 services; 2024 $1.8M for 173,395 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 86235 Immunoassay | 1,841 | 209 | $17.57 | $32K |
| 85651 Clinical Chemistry | 1,749 | 698 | $4.17 | $7,296 |
| 36415 Venipuncture Blood Collection | 1,742 | 698 | $7.98 | $14K |
| 85025 Blood Count | 1,738 | 698 | $7.60 | $13K |
| 86141 Clinical Chemistry | 1,707 | 686 | $12.66 | $22K |
| 84160 Clinical Chemistry | 1,630 | 666 | $5.50 | $8,960 |
| 82565 Clinical Chemistry | 1,629 | 666 | $5.02 | $8,178 |
| 84520 Clinical Chemistry | 1,628 | 666 | $3.87 | $6,300 |
| 82150 Clinical Chemistry | 1,626 | 666 | $6.35 | $10K |
| 84075 Clinical Chemistry | 1,625 | 665 | $5.08 | $8,255 |
Medicare prescription drug claims, 2024
In 2024, the drug Joo-Hyung Lee prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 474 prescriptions and refills. In total Joo-Hyung Lee wrote 4,151 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 474 | 1,005 | 154 | $14K |
| Hydroxychloroquine Sulfate Generic | 419 | 934 | 160 | $24K |
| Prolia Denosumab | 301 | 1,794 | 190 | $509K |
| Celecoxib Generic | 256 | 530 | 106 | $11K |
| Prednisone Generic | 238 | 319 | 104 | $1,677 |
| Leflunomide Generic | 164 | 376 | 61 | $11K |
| Humira(Cf) Pen Adalimumab | 135 | 140 | 25 | $1.1M |
| Tramadol Hcl Generic | 124 | 124 | 41 | $961 |
| Folic Acid Generic | 96 | 280 | 46 | $829 |
| Allopurinol Generic | 96 | 262 | 37 | $1,501 |
| Diclofenac Sodium Generic | 95 | 162 | 39 | $1,845 |
| Duloxetine Hcl Generic | 86 | 200 | 32 | $2,172 |
| Enbrel Sureclick Etanercept | 82 | 82 | 15 | $591K |
| Gabapentin Generic | 79 | 152 | 35 | $996 |
| Meloxicam Generic | 64 | 157 | 23 | $317 |
Brand drugs: 1,153 claims; generic drugs: 2,967 claims; opioid claims: 213.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joo-Hyung Lee $4,754 ($4,754 in general payments such as food, travel and fees) from 26 companies. The largest payer was Amgen Inc. with $1,062.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 53 | $1,062 |
| Abbvie Inc. ABBV | 24 | $559 |
| Lilly USA, LLC LLY | 16 | $508 |
| UCB, Inc. UCB.BR | 11 | $349 |
| Mallinckrodt Hospital Products Inc. | 8 | $308 |
| Pfizer Inc. PFE | 10 | $249 |
| GlaxoSmithKline, LLC. GSK | 9 | $221 |
| Organon LLC OGN | 8 | $186 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $183 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $137 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.